Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors

被引:21
作者
Mandanas, RA [1 ]
Saez, RA [1 ]
Epstein, RB [1 ]
Confer, DL [1 ]
Selby, GB [1 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect,Blood & Marrow Transplantat Pr, Oklahoma City, OK USA
关键词
germ cell tumors; bone marrow transplantation; relapsed; cisplatin-refractory;
D O I
10.1038/sj.bmt.1701132
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Twenty-one patients with relapsed or refractory germ cell tumors were treated with high-dose chemotherapy and marrow transplantation (HDC/BMT) from 1982-1993, Primary sites of disease were testis (17), ovary (three), and pineal gland (one), Pathology included dysgerminoma (one), choriocarcinoma with adenocarcinoma (one), seminoma (four), and nonseminoma or mixed germ cell tumor (15), Nineteen had at least two prior chemotherapy regimens and eight had cisplatin-refractory disease defined as progression within 4 weeks of a cycle of cisplatin-based chemotherapy. HDC regimens were mostly combinations of cyclophosphamide with etoposide and cisplatin or carboplatin, There were only two treatment-related deaths (aspergillosis and interstitial pneumonitis), Times to engraftment of granulocytes (21 +/- 8.3 days) and platelets (32 +/- 20.2 days) were reasonable with only the last nine patients receiving growth factors, At a minimum of 4 years follow-up, eight patients have died of disease, six of whom were cisplatin-refractory prior to transplant, Eleven patients (52% overall) are alive and continuously free of disease after 4-10 years including one of three with refractory ovarian germ cell tumor, HDC/BMT provides significant long-term disease-free survival as salvage therapy for both male and female relapsed germ cell tumor patients who are not refractory to cisplatin.
引用
收藏
页码:569 / 576
页数:8
相关论文
共 30 条
[21]   High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity [J].
Motzer, RJ ;
Mazumdar, M ;
Bosl, GJ ;
Bajorin, DF ;
Amsterdam, A ;
Vlamis, V .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1098-1105
[22]   PHASE-II TRIAL OF HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN 1ST-LINE THERAPY FOR PATIENTS WITH POOR-RISK GERM-CELL TUMORS [J].
MOTZER, RJ ;
MAZUMDAR, M ;
GULATI, SC ;
BAJORIN, DF ;
LYN, P ;
VLAMIS, V ;
BOSL, GJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (22) :1828-1835
[23]   HIGH-DOSE CHEMOTHERAPY FOR RESISTANT GERM-CELL TUMORS - RECENT ADVANCES AND FUTURE-DIRECTIONS [J].
MOTZER, RJ ;
BOSL, GJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (22) :1703-1709
[24]  
MOTZER RJ, 1992, CANCER-AM CANCER SOC, V69, P550, DOI 10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO
[25]  
2-D
[26]   HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN REFRACTORY GERM-CELL CANCER - AN EASTERN COOPERATIVE ONCOLOGY GROUP PROTOCOL [J].
NICHOLS, CR ;
ANDERSEN, J ;
LAZARUS, HM ;
FISHER, H ;
GREER, J ;
STADTMAUER, EA ;
LOEHRER, PJ ;
TRUMP, DL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :558-563
[27]   DOSE-INTENSIVE CHEMOTHERAPY IN REFRACTORY GERM-CELL CANCER - A PHASE-I/II TRIAL OF HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
NICHOLS, CR ;
TRICOT, G ;
WILLIAMS, SD ;
VANBESIEN, K ;
LOEHRER, PJ ;
ROTH, BJ ;
AKARD, L ;
HOFFMAN, R ;
GOULET, R ;
WOLFF, SN ;
GIANNONE, L ;
GREER, J ;
EINHORN, LH ;
JANSEN, J .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) :932-939
[28]   PILOT-STUDY OF A HIGH-DOSE CARBOPLATIN-BASED SALVAGE STRATEGY FOR RELAPSING OR REFRACTORY GERM-CELL CANCER [J].
RODENHUIS, S ;
VANDERWALL, E ;
HUININK, WWT ;
SCHORNAGEL, JH ;
RICHEL, DJ ;
VLASVELD, LT .
CANCER INVESTIGATION, 1995, 13 (04) :355-362
[29]   TECHNIQUE FOR HUMAN MARROW GRAFTING [J].
THOMAS, ED ;
STORB, R .
BLOOD-THE JOURNAL OF HEMATOLOGY, 1970, 36 (04) :507-&
[30]  
Williams S D, 1992, Semin Oncol, V19, P19